

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 June 2008 (19.06.2008)

PCT

(10) International Publication Number
WO 2008/071961 A1

(51) International Patent Classification:

C07D 493/04 (2006.01) A61K 31/4709 (2006.01)
C07D 498/04 (2006.01) A61K 31/498 (2006.01)
C07D 513/04 (2006.01) A61P 31/00 (2006.01)

(21) International Application Number:

PCT/GB2007/004766

(22) International Filing Date:

13 December 2007 (13.12.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/870,181 15 December 2006 (15.12.2006) US
60/969,163 30 August 2007 (30.08.2007) US

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM only):
ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COMITA-PRE-VOIR, Janelle [US/US]; AstraZeneca R & D Boston, 35

Gatehouse Drive, Waltham, Massachusetts 02451 (US).
CRONIN, Mark [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US).
GENG, Bolin [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US).
GODFREY, Andrew, Aydon [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **RECK, Folkert** [DE/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, MA 02451 (US).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS



(I)

(57) Abstract: The present invention relates to compounds of Formula (I) : and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.